News & Updates

Show Multimedia Only

DOACs as good as LMWH for recurrent VTE prevention in cancer patients

29 Jun 2023

For patients with cancer who have recurrent venous thromboembolism (VTE), direct oral anticoagulants (DOACs) compare favourably with low-molecular-weight heparin (LMWH) in terms of recurrence prevention, according to a study.

29 Jun 2023

Real-world data back CV safety of JAK inhibitors

28 Jun 2023 by

Two real-world studies presented at EULAR 2023 reflected the cardiovascular (CV) safety of Janus kinase inhibitors (JAKi*) in patients with rheumatoid arthritis (RA).

28 Jun 2023

Bempedoic acid beneficial for prevention of cardiac events in high-risk patients

28 Jun 2023

The use of bempedoic acid in primary prevention appears to lower the incidence of major cardiovascular events for high-risk patients, as shown in the subgroup analysis of the CLEAR Outcomes* trial.

28 Jun 2023

$Uricase-based combo therapy promising for refractory gout$

Uricase-based combo therapy promising for refractory gout

28 Jun 2023 by

Half of gout patients receiving novel uricase analogue infusions, along with a proprietary rapamycin formulation, got their serum urate controlled in two phase III studies presented at EULAR 2023.

28 Jun 2023

Sacituzumab govitecan proven safe, effective in metastatic breast cancer

26 Jun 2023 by

Treatment with sacituzumab govitecan (SG) demonstrates clinically meaningful overall survival (OS) over single-agent chemotherapy in patients with pretreated, endocrine-resistant, hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic breast cancer (mBC), as confirmed by the final OS analysis from the TROPiCS-02 study, presented at ASCO 2023.

26 Jun 2023

Symptom-based protocol improves management of anticancer therapy infusion reactions

26 Jun 2023

Implementation of a novel pharmacist-developed, symptom-based, nurse-driven protocol has led to a low failure rate in infusion reaction treatment among infusion-related reactions (IRRs) assessed, results of a study have shown.

26 Jun 2023

Pembrolizumab well tolerated, effective in NSCLC with autoimmune disease

25 Jun 2023

Use of pembrolizumab is well tolerated in nonsmall cell lung cancer (NSCLC) patients with previous autoimmune diseases, with a nonsignificant trend toward improved outcomes, reports a study.

25 Jun 2023

Dolutegravir safe, effective in paediatric HIV

24 Jun 2023

Use of dolutegravir (DTG) proves to be effective and safe in children and adolescents living with HIV (CALHIV) in low- and middle-income countries (LMICs), as shown in a study.

24 Jun 2023